61
CanSino Biologics Inc.
6185.HK · HKSE
$29.60 +3.86% (+$1.10)
1M +16.42%
Market Cap ¥8.80B
P/E Ratio 216.55x
Div. Yield -
ROE 0.82%
Piotroski F-Score Moderate
6/9Valuation
16 /100
Expensive P/S 7.17x
P/E 216.55x
P/B 1.77x
Growth
16 /100
Declining Book val. growth 9.78%
Rev. growth 0.03%
FCF growth N/A
Profitability
25 /100
Weak Op. margin 4.62%
Gross margin 71.69%
FCF margin 10.47%
Quality
4 /100
Poor ROA 0.59%
ROIC 0.82%
Asset turnover 0.18x
Debt
80 /100
Low Int. coverage -2.08x
Debt/Equity 0.20x
Net debt/EBITDA -5.05x
Stability
18 /100
Unstable EPS volatility 90.50%
Beta 1.22x
Profitable years 1
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na 6185.HK
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Xue Feng Yu
Employees
1,134
Headquarters
Tianjin
Nadcházející události
02 LIS
Earnings
Upcoming earnings report
30 BŘE
Earnings
Upcoming earnings report